Schrödinger is the scientific leader in developing state-of-the-art chemical simulation software for use in pharmaceutical, biotechnology, and materials research.

難溶性薬物の放出メカニズムを解明する – ASD研究の新たなアプローチ | Modelling amorphous solid dispersion (ASD) release mechanisms OCT 15, 2025 | AbbVie と Schrödinger のエキスパートが …

Our mission is to improve human health and quality of life by transforming the way therapeutics and materials are discovered.

6 days ago · The problem: Developing next-generation energy storage solutions requires a deep understanding of complex, multiscale phenomena—from ion transport in electrolytes to the reactive …

Headquartered in New York City, Schrödinger has multiple offices around the world including the USA, the UK, Germany, India, and Japan.

We are leveraging our computational platform and massive computing power to advance our proprietary programs both independently and in collaboration with leading biotech and pharmaceutical companies.

Our physics-based computational platform integrates differentiated solutions for predictive modeling, data analytics, and collaboration to enable rapid exploration of chemical space.

Feb 24, 2026 · Schrödinger is transforming the way therapeutics and materials are discovered. Learn more about our company.

Schrödinger’s collaborative leadership team is committed to achieving the best possible outcomes for our customers, partners, patients, and other stakeholders.

Jan 12, 2026 · Schrdinger, Inc. (Nasdaq: SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to focus on …